# Bicycle Therapeutics plc American (BCYC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.30, market value $301 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bicycle Therapeutics plc American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 4.9×**. Each dollar of revenue is priced at 4.9×.
- **Price / book: 0.6×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **EV / EBITDA: 1.4×**. Enterprise value is 1.4× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: -69.2%** (5-yr avg -18.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -343.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -301.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -35.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -26.5%**. Each dollar of assets produces -26.5% of profit.

## Growth
- **Revenue growth (1 yr): 105.8%** (3-yr 71.2%/yr, 5-yr 47.5%/yr). Revenue grew 105.8% over the last year, against 47.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -9.0%**. Earnings per share fell 9.0%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.05**. Debt is 0.05 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.9×**. It would take 2.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 11.98** (quick 11.98). Current assets cover the next year's liabilities 11.98 times.
- **Altman Z-score: 2.88**. A Z-score of 2.88 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Bicycle Therapeutics plc American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (6 analysts). 6 analysts cover Bicycle Therapeutics plc American; the consensus is buy, with an average price target of $9.50 (+121% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -38.3%** (YTD -39.3%, 3-mo 2.4%). The shares are down 38.3% over twelve months including dividends.
- **From 52-week high: -53.1%** (14.8% above the low). Trading 53% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.36** (volatility 51%). Beta of 1.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BCYC · Page: https://foliofundamentals.com/stocks/bcyc

Not investment advice.